Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 73

Results For "S-1"

1012 News Found

Lupin receives USFDA approval for Pregabalin and Iloperidone
Drug Approval | May 06, 2022

Lupin receives USFDA approval for Pregabalin and Iloperidone

While Pregabalin will be manufactured at the Aurangabad facility, Iloperidone will be manufactured at the Goa facility


JBCPL emerges as the fastest growing pharma company: Report
News | May 05, 2022

JBCPL emerges as the fastest growing pharma company: Report

Ranked 25th with an impressive growth rate of 29% among Indian pharma companies in FY 2021-22


Eris Lifesciences acquires Oaknet Healthcare for Rs 650 crore
News | May 04, 2022

Eris Lifesciences acquires Oaknet Healthcare for Rs 650 crore

The deal will be financed by Rs 300 crore of internal accruals and Rs 350 crore of borrowings


GOQii launches first of its kind one-stop solution for Diabetes care in India
Startup | May 04, 2022

GOQii launches first of its kind one-stop solution for Diabetes care in India

An Integrated programme comprising GOQii device, Glucometer – Contour Plus+1 from Ascensia Diabetes Care India and personalised diabetes coaching


Pfizer sets up global drug development centre in Chennai
News | May 04, 2022

Pfizer sets up global drug development centre in Chennai

The facility is among 12 centres established worldwide, and the first in Asia


StanPlus appoints Gurjit Singh as COO and Founding Member
People | May 02, 2022

StanPlus appoints Gurjit Singh as COO and Founding Member

He will be leading the business, operations, P&L, and growth strategy for StanPlus


USFDA approves Rinvoq as an oral treatment for ankylosing spondylitis
Drug Approval | May 01, 2022

USFDA approves Rinvoq as an oral treatment for ankylosing spondylitis

The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases


Beta Drugs announces oultook for FY 22-23
News | April 28, 2022

Beta Drugs announces oultook for FY 22-23

The management believes that its strong product pipeline, diversified innovative product portfolio, continued expansion into new geographies and FGMP accreditations will help sustain the growth momentum in the coming few years


Sanofi continues to deliver strong business
News | April 28, 2022

Sanofi continues to deliver strong business

Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate


USFDA grants Breakthrough Device designation to Nocria’s Migraine treatment
Biotech | April 28, 2022

USFDA grants Breakthrough Device designation to Nocria’s Migraine treatment

Nocria’s hand-held device uses gentle, controlled puffs of air in the ears for treating migraine attacks